Company Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Legend Biotech Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
43.98 ^USD	+0.55%		-2.63%	-26.91%

23/04	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
22/04	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Number of employees: 1,800

USD in Million	2022	Weight	2023	Weight	Delta
Novel Cell Therapies 100.0 %	117	100.0 %	285	100.0 %	+143.70%

USD in Million	2022	Weight	2023	Weight	Delta
United States 94.7 %	117	99.7 %	270	94.7 %	+131.47%
Europe 5.3 %	0	0.1 %	15	5.3 %	+19,993.33%
China 0.1 %	0	0.3 %	0	0.1 %	-45.43%

Managers	Title	Age	Since
Ying Huang CEO	Chief Executive Officer	51	01/19/01
Lori Macomber DFI	Director of Finance/CFO	53	01/19/01
Tracy Luo CTO	Chief Tech/Sci/R&D Officer	-	01/18/01
Liz Gosen CTO	Chief Tech/Sci/R&D Officer	-	01/19/01
Guowei Fang CTO	Chief Tech/Sci/R&D Officer	-	01/22/01
Mythili Koneru CTO	Chief Tech/Sci/R&D Officer	46	11/23/11
Crystal Chen		-	-
Jessie Yeung IRC	Investor Relations Contact	-	01/19/01
Elaine Qian HRO	Human Resources Officer	-	01/19/01
Yuhong Qiu LAW	General Counsel	-	01/18/01

Members of the board	Title	Age	Since
Ying Huang CEO	Chief Executive Officer	51	01/19/01
Corazon Sanders BRD	Director/Board Member	67	01/20/01
Li Zhu BRD	Director/Board Member	74	23/20/23
Patrick J. Casey BRD	Director/Board Member	68	03/20/03
Fang Liang Zhang CEO	Chief Executive Officer	59	27/15/27
Tomas Jan Heyman BRD	Director/Board Member	68	02/22/02
Ye Wang BRD	Director/Board Member	55	01/15/01
Wai Man Yau BRD	Director/Board Member	48	01/20/01
Xiao Hui Ji BRD	Director/Board Member	62	01/20/01
Li Mao BRD	Director/Board Member	67	02/22/02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	363,822,069	360,183,848 ( 99.00 %)	0	99.00 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 7.035 %	12,797,994	7.035 %	718 M $
T. Rowe Price International Ltd. 5.941 %	10,808,216	5.941 %	606 M $
RA Capital Management LP 3.444 %	6,264,707	3.444 %	351 M $
HHLR Advisors Ltd. (Cayman Islands) 3.290 %	5,984,550	3.290 %	336 M $
BlackRock Advisors LLC 2.272 %	4,133,809	2.272 %	232 M $
Capital Research & Management Co. (World Investors) 1.312 %	2,385,960	1.312 %	134 M $
Wellington Management Co. LLP 1.268 %	2,306,391	1.268 %	129 M $
Massachusetts Financial Services Co. 1.091 %	1,984,826	1.091 %	111 M $
Paradigm BioCapital Advisors LP 1.042 %	1,894,644	1.042 %	106 M $
Janus Henderson Investors US LLC 1.025 %	1,865,157	1.025 %	105 M $

Name	Equities	%	Valuation
GENSCRIPT BIOTECH CORPORATION 60.32 %	174,497,556	60.32 %	4 894 M $
Aquapoint LP 10.48 %	30,320,000	10.48 %	850 M $
Hillhouse Investment Management Ltd. 3.552 %	10,273,234	3.552 %	288 M $
Fang Liang Zhang 0.3690 %	1,067,386	0.3690 %	30 M $
Xiao Hui Ji 0.006698 %	19,376	0.006698 %	543 400 $
Corazon Sanders 0.006698 %	19,376	0.006698 %	543 400 $
Wai Man Yau 0.006698 %	19,376	0.006698 %	543 400 $
Lori Macomber 0.005259 %	15,212	0.005259 %	426 621 $
Patrick J. Casey 0.004733 %	13,690	0.004733 %	383 936 $
Ying Huang 0.003909 %	11,306	0.003909 %	317 077 $

Legend Biotech Corp.

2101 Cottontail Lane

08873, Somerset

+732 317 5050

http://www.legendbiotech.com

address Legend Biotech Corporation(LEGN)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

43.98 USD

Average target price

86.33 USD

Spread / Average Target

+96.29%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
LEGEND BIOTECH CORPORATION	-26.91%	7.96B
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs